97 related articles for article (PubMed ID: 30504414)
1. Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in
Eoh KJ; Park HS; Park JS; Lee ST; Han JW; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Anticancer Res; 2018 Dec; 38(12):6947-6953. PubMed ID: 30504414
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
[TBL] [Abstract][Full Text] [Related]
3. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie O; Chetrit A; Novikov I; Sadetzki S;
Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
[TBL] [Abstract][Full Text] [Related]
4. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G; Giannone G; Valabrega G; Maggiorotto F; Genta S; Pignata S; Lorusso D; Cormio G; Scalone S; Nicoletto MO; Greco F; Rossi E; Spagnoletti I; De Giorgi U; Orditura M; Mosconi AM; Kardhashi A; Bogliolo S; Borgato L
Gynecol Oncol; 2021 Jun; 161(3):755-761. PubMed ID: 33888336
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
De Nonneville A; Zemmour C; Frank S; Joly F; Ray-Coquard I; Costaz H; Classe JM; Floquet A; De la Motte Rouge T; Colombo PE; Sauterey B; Leblanc E; Pomel C; Marchal F; Barranger E; Savoye AM; Guillemet C; Petit T; Pautier P; Rouzier R; Gladieff L; Simon G; Courtinard C; Sabatier R
Gynecol Oncol; 2021 Oct; 163(1):64-71. PubMed ID: 34294414
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
Kotoula V; Lakis S; Tikas I; Giannoulatou E; Lazaridis G; Papadopoulou K; Manoussou K; Efstratiou I; Papanikolaou A; Fostira F; Vlachos I; Tarlatzis B; Fountzilas G
Gynecol Oncol; 2019 Feb; 152(2):375-386. PubMed ID: 30446274
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
10. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
[TBL] [Abstract][Full Text] [Related]
12. [Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis].
Tao T; Yang JX; Shen K; Cao DY
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):20-25. PubMed ID: 28190311
[No Abstract] [Full Text] [Related]
13. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
Pradjatmo H; Dasuki D; Anwar M; Mubarika S; Harijadi
Asian Pac J Cancer Prev; 2014; 15(21):9479-85. PubMed ID: 25422243
[TBL] [Abstract][Full Text] [Related]
14. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
Ramus SJ; Harrington PA; Pye C; DiCioccio RA; Cox MJ; Garlinghouse-Jones K; Oakley-Girvan I; Jacobs IJ; Hardy RM; Whittemore AS; Ponder BA; Piver MS; Pharoah PD; Gayther SA
Hum Mutat; 2007 Dec; 28(12):1207-15. PubMed ID: 17688236
[TBL] [Abstract][Full Text] [Related]
15. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
16. Screening for
Al-Qahtani WS; Alduwish MA; Al-Olayan EM; Aljarba NH; Em AH; Albani FG; Domiaty DM; Al-Otaibi AM; Qattan SMA; Almurshedi AS; Elasbali AM; Ahmed HG; Almutlaq BA
J Obstet Gynaecol; 2021 Oct; 41(7):1127-1133. PubMed ID: 33475035
[TBL] [Abstract][Full Text] [Related]
17. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
19. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
20. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]